In Acquisition By Opko, Prolor Poised To Become U.S. Firm’s Biologics Subsidiary

Opko’s third investment in the Israeli biopharmaceutical sector is a $480 million all-stock deal in which it will acquire Prolor Biotech, which specializes in developing longer-acting formulations of approved protein products. Its lead candidate is human growth hormone hGH-CTP, in development for growth hormone deficiency in adults and children.

Opko Health Inc.’s busy first half of 2013 continued April 24 with the announcement that it will acquire Israel’s Opko Biologics in an all-stock transaction valued at roughly $480 million.

The deal, expected to close during the second half of this year, is structured so that Prolor’s management and personnel...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

Organ-On-A-Chip: Upcoming US FDA Guidance Could Help Flesh Out ‘Roadmap’

 

The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.

Access Risks Loom For All Drugmakers With Fourth Circuit Mifepristone Decision

 

The FDA law establishing REMS authority does not preempt a West Virginia law that would restrict mifepristone use in the state, an appeals court said, a decision that could have broader ramifications for the agency’s authority to ensure drug access.

More from North America